Trinity Biotech (TRIB) Gross Profit (2009 - 2024)

Trinity Biotech (TRIB) has reported Gross Profit for 16 consecutive years, with $4.9 million the latest figure, recorded in Q4 2024.

• Quarterly Gross Profit rose 6.79% year-over-year to $4.9 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $21.4 million (up 10.24% YoY) and the FY2025 annual result came in at $16.9 million, down 21.24% from the prior year.
• Gross Profit fell to $4.9 million in Q4 2024 per TRIB's latest filing, from $5.3 million in the prior quarter.
• Over the last five years, Gross Profit for TRIB reached as high as $16.8 million in Q3 2020 and fell as low as $329000.0 in Q3 2022.
• A 5-year average of $7.2 million and a median of $5.7 million in 2022 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2022 — Gross Profit tumbled 96.3% — and 2023, when it surged 1200.91%.
• Year by year, Gross Profit stood at $15.7 million in 2020, then slumped by 53.77% to $7.2 million in 2021, then retreated by 25.75% to $5.4 million in 2022, then fell by 15.03% to $4.6 million in 2023, then rose by 6.79% to $4.9 million in 2024.
• According to Business Quant data, Gross Profit over the past three periods registered $4.9 million, $5.3 million, and $5.7 million for Q4 2024, Q3 2024, and Q2 2024 respectively.